The journal, which was launched by the SFCNS in 2021, has received its first Impact Factor - a major step in its scientific recognition.

We are delighted to announce a significant achievement in the development of the journal Clinical and Translational Neuroscience (CTN): for the first time, the journal has received an official Impact Factor. With a rating of 1.1, this recognition marks a pivotal moment in the scientific establishment of CTN.

The release of the journal’s first Impact Factor is more than just a numerical milestone - it is a validation of the vision behind CTN. Since its founding in 2021, the journal has aimed to bridge the gap between basic and clinical neuroscience and foster exchange across the diverse fields of neurological science. CTN publishes high-quality, peer-reviewed, open access research that supports neuroscientists in enhancing patient care, promoting education, and advancing professionalism in the field.

In addition to receiving an Impact Factor, CTN was accepted into Scopus in April 2025, further underlining the journal’s growing influence and reputation in the international scientific community. These achievements reflect the steady rise of CTN as a respected platform for transdisciplinary neuroscience research.

This success would not have been possible without the dedication of our editorial board, reviewers, authors, and readers. We extend our heartfelt thanks to all those who have contributed their expertise, time, and trust in CTN. Your commitment has played a crucial role in reaching this important milestone.

CTN is owned by the Swiss Federation of Clinical Neuro-Societies and has been published quarterly online by MDPI since July 2021. We look forward to continuing this journey together and invite researchers and clinicians alike to contribute to and engage with CTN as we further its mission.